ELISA. Western blot: 0.5 - 1 μg/mL. Immunoflourescence. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS containing 0.02 % sodium azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
TARDBP antibody, TDP43 antibody, DKFZp459I2127 antibody, tardbp antibody, ALS10 antibody, TDP-43 antibody, 1190002A23Rik antibody, C85084 antibody, Tdp43 antibody, wu:fb77f02 antibody, wu:fc52g10 antibody, TAR DNA binding protein antibody, Tardbp protein antibody, TAR DNA binding protein L homeolog antibody, TAR DNA-binding protein 43-like antibody, TARDBP antibody, tardbp antibody, tardbp.L antibody, Tardbp antibody, LOC100621383 antibody
Background
TDP43 was initially identified as a novel cellular protein that bound to HIV-1 virus TAR DNA sequence motifs and acts a transcriptional repressor to the HIV-1 LTR. Later experiments revealed that TDP43 also regulates the splicing of exon 9 of the cystic fibrosis transmembrane conductance regular (CFTR), most likely through the association with the UG repeats at the 3' splice site. A hyperphosphorylated, ubiquitinated, and cleaved form of TDP43 known as pathologic TDP43 is the major disease protein in ubiquitin-positive, tau-, and alpha-synuclein-negative frontotemporal dementia (FLTD-U). TDP43 is not related to TRBP1, and RNA binding protein that binds HIV-1 TAR RNA sequences. At least two isoforms are known to exist for this protein, this TDP43 antibody only recongizes the longer of the two isoforms.Synonyms: TAR DNA-binding protein 43, TDP-43, TDP43